“Development and Evaluation of High-Concentration Human Immune Globulin Suspension Formulations”

Ashvini Kumar Mishra

“Development and Evaluation of High-Concentration Human Immune Globulin Suspension Formulations”

Authors: Ashvini Kumar Mishra

Published: 2025-03-06 12:17:20.084

Abstract

The development of high-concentration human immune globulin suspension formulations requires a deep understanding of formulation strategies, injectability challenges, and colloidal stability. This study investigates the impact of spray drying, excipient-induced protein saturation, concentration-injection force relationships, viscosity behavior, and clinical implications of non-Newtonian suspensions. A quantitative research methodology was employed, analyzing independent variables such as spray drying conditions, excipient concentrations, and formulation parameters against dependent variables including particle size distribution, protein solubility, injection force, and viscosity. The results demonstrate that optimized spray drying significantly improves particle size uniformity, pharmaceutical excipients enhance protein solubility while maintaining stability, higher concentration suspensions require greater injection force, viscosity increases with concentration affecting injectability, and formulation strategies can mitigate injectability challenges to enhance clinical viability. The findings contribute to improved formulation techniques for injectable high-viscosity suspensions, addressing gaps in drug delivery and biopharmaceutical manufacturing. Future research should explore long-term stability, forced degradation, and regulatory considerations for clinical translation.

Keywords

High-concentration immune globulin, spray drying, injectability, viscosity, pharmaceutical excipients, protein saturation, colloidal stability, formulation strategies, drug delivery, biopharmaceuticals.

References

Rathore, N., & Rajan, R. S. (2008). Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnology Progress, 24(3), 504-514.
Wang, W. (2015). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 493(1-2), 70-84.
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 544-575.
Maa, Y. F., & Prestrelski, S. J. (2000). Biopharmaceutical powders: particle formation and formulation considerations. Current Pharmaceutical Biotechnology, 1(3), 283-302.
Chan, H. K., & Kwok, P. C. L. (2011). Production methods for spray-dried protein pharmaceuticals. Advanced Drug Delivery Reviews, 63(13), 923-939.
Mahler, H. C., Friess, W., Grauschopf, U., & Kiese, S. (2009). Protein aggregation: pathways, induction factors and analysis. Journal of Pharmaceutical Sciences, 98(9), 2909-2934.
Carpenter, J. F., & Randolph, T. W. (2017). Protein excipients: Why and how? Journal of Pharmaceutical Sciences, 106(4), 862-865.
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014). Immunogenicity of therapeutic proteins: Influence of aggregation. Journal of Immunotoxicology, 11(2), 99-109.
Shire, S. J., Shahrokh, Z., & Liu, J. (2004). Challenges in the development of high protein concentration formulations. Journal of Pharmaceutical Sciences, 93(6), 1390-1402.
Roberts, C. J. (2014). Non-native protein aggregation kinetics. Biotechnology and Bioengineering, 111(1), 20-25.

Download PDF

How to Cite

Ashvini Kumar Mishra, (2025-03-06 12:17:20.084). “Development and Evaluation of High-Concentration Human Immune Globulin Suspension Formulations”. JANOLI International Journal of Pharmaceuticals and Chemicals, Volume t8VTiGjctuTvNUTp50bc, Issue 1.

ISSN: A/F

JANOLI International Journal of
Pharmaceuticals and Chemicals ( JIJPC )